CLGN (CollPlant Biotechnologies) Total Assets: $9.18 Mil (As of Mar. 2026)


CLGN CollPlant Biotechnologies Ltd CLGN
35 GF Score
Price $0.35
GF Value $0.29
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CollPlant Biotechnologies Total Assets?

CollPlant Biotechnologies CLGN -0.03% 35 Total Assets is $9.18 Mil as of Mar. 2026. GuruFocus rates CLGN with a GF Score™ of 35/100 and a GF Value™ of $0.29 (Modestly Overvalued). The stock has 4 warning signs investors should review.

CollPlant Biotechnologies's Total Assets for the quarter that ended in Mar. 2026 was $9.18 Mil.

During the past 12 months, CollPlant Biotechnologies's average Total Assets Growth Rate was -24.00% per year. During the past 3 years, the average Total Assets Growth Rate was -13.80% per year. During the past 5 years, the average Total Assets Growth Rate was -6.60% per year. During the past 10 years, the average Total Assets Growth Rate was 12.30% per year.

During the past 13 years, CollPlant Biotechnologies's highest 3-Year average Total Assets Growth Rate was 36.60%. The lowest was -13.80%. And the median was 15.65%.

Total Assets is connected with ROA %. CollPlant Biotechnologies's annualized ROA % for the quarter that ended in Mar. 2026 was -124.08%. Total Assets is also linked to Revenue through Asset Turnover. CollPlant Biotechnologies's Asset Turnover for the quarter that ended in Mar. 2026 was 0.01.

CollPlant Biotechnologies  (NAS:CLGN) Total Assets Explanation

Total Assets is connected with ROA %.

CollPlant Biotechnologies's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-12.388/( (10.785+9.183)/ 2 )
=-12.388/9.984
=-124.08 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

CollPlant Biotechnologies's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.073/( (10.785+9.183)/ 2 )
=0.073/9.984
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

CollPlant Biotechnologies Total Assets Related Terms

CollPlant Biotechnologies Total Assets Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies Total Assets Chart

CollPlant Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.22 37.77 34.13 18.71 10.79

CollPlant Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.21 17.44 14.09 10.79 9.18
CLGN
35GF Score
CollPlant Biotechnologies Ltd CLGN
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CollPlant Biotechnologies Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

CollPlant Biotechnologies's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=6.081+4.704
=10.79

CollPlant Biotechnologies's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=4.886+4.297
=9.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $9.18 Mil mean?
CollPlant Biotechnologies (CLGN) has a Total Assets of $9.18 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on CollPlant Biotechnologies and its competitors.
Is CollPlant Biotechnologies' Total Assets too high?
CollPlant Biotechnologies' current Total Assets is $9.18 Mil. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Total Assets compare to CPMV and TCRT?
CollPlant Biotechnologies' Total Assets of $9.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current Total Assets is $9.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.35 — trading 19.9% above its estimated fair value. The current Total Assets is $9.18 Mil. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current Total Assets is $9.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of $0.35 is trading 19.9% above its estimated GF Value™ of $0.29. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for CLGN:

  • Total Assets: $9.18 Mil
  • GF Value™: $0.29 vs. price of $0.35 (19.9% above fair value)
  • GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CollPlant Biotechnologies Business Description

Other Exchanges CPT:Germany
Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score

Get the complete analysis for CLGN

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price
$0.29
GF Value